Solos Endoscopy Finishes 2012 Strong

Jan 16, 2013, 12:35 ET from Solos Endoscopy, Inc.

BOSTON, Jan. 16, 2013 /PRNewswire/ -- Solos Endoscopy, Inc. (OTCPK: SNDY) is pleased to announce that the Company experienced an approximate 16% increase in sales for the twelve months ended 2012 compared to 2011.  Solos Endoscopy finished 2012 with $395,038.76 in sales, a 16% increase over 2011 sales of $340,626.22.

Solos Endoscopy's increase in sales for the twelve months ended 2012 can be attributed to a strong fourth quarter where the Company had three months of sales increases compared to the prior year.  In October, Solos Endoscopy posted sales of $37,274.90; this represented an approximate 36% increase from the year prior sales of $27,455.52.  In the month of November, sales increased by more than 53%; with sales of $27,818.96 for November 2011 compared to $42,631.56 for November 2012.  In December 2012, Solos Endoscopy posted sales of $42,043.02 compared to $21,363.69 for the same period in 2011; this represented a 97% increase.

Solos management is pleased that it has been able to achieve these sales increases without any significant changes to its pricing or operations. In addition, management has previously announced that it has taken steps to increase the shelf life of its sterilized endoscopic instruments which should allow hospitals to order product in larger quantities. Solos Endoscopy posts its financial reports and disclosures according to OTC Market Guidelines.  These disclosures can be viewed at  

Solos Endoscopy instruments are FDA approved.  The Company recently retained TUV SUD America, Inc. to complete its ISO 13485 Certification and Audit on its instruments including the MammoView®.  The Company previously engaged Expert Resource to prepare the Company for the final audit.  Expert Resource will attend the final audit, and help interpret any findings. According to Expert Resource, their consultants maintain a 100% success rate of passing the final audit on the first attempt. Solos Endoscopy has posted its updated ISO 13485 CE Mark Schedule on its website,

About Solos Endoscopy, Inc.:

Solos Endoscopy is celebrating its 25th Year of providing quality innovative healthcare instruments to Hospitals across the Country.  For more than 25 Years, from medical schools to hospitals, surgeons have trusted Solos Endoscopy to develop and market breakthrough technology, applications, medical devices, and procedural techniques for the screening, diagnosis, treatment and management of disease and medical conditions.

Additional information on its FDA approved products is available on the Company's website at:

Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Technical complications that may arise could prevent the prompt implementation of any strategically significant plan(s) outlined above. The company cautions that these forward-looking statements are further qualified by other factors including, but not limited to, those set forth in the company's Annual Report filing and other filings with the OTC Markets Group (available at The company undertakes no obligation to publicly update or revise any statements in this release, whether as a result of new information, future events, or otherwise.

Investor Relations
(617) 360-9719


SOURCE Solos Endoscopy, Inc.